Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial
Results demonstrated inclisiran to have met both primary end points with a favorable safety profile.
Brian Park, PharmD
Drug Information Specialist https://www.medicalbag.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.
